Tratamiento de la endocarditis y otras infecciones graves producidas por enterococos

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 14, Issue 3, 1996, Pages 186-191

  Fernández Guerrero, Manuel L ^a  

^a Div de Enfermedades Infecciosas   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; GENTAMICIN; PENICILLIN G; VANCOMYCIN;

BACTERIAL ENDOCARDITIS; ENTEROCOCCUS; HUMAN; REVIEW; SPAIN;

DRUG RESISTANCE, MICROBIAL; ENDOCARDITIS, BACTERIAL; ENTEROCOCCUS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS;

EID: 0029927702     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (74)

1. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med 1991; 9 supl 3B: 72-75.
2. Morrison AJ, Wenzel RP. Nosocomial urinary tract infection due to enterococcus: ten years' experience at a university hospital. Arch Intern Med 1986; 146: 1.549-1.551.
3. Zervos MJ, Bacon AE, Patterson JE, Schaberg DR, Kauffman CA. Enterococcal superinfection in patients treated with ciprofloxacin. J Antimicrob Chemother 1988; 121: 113-115.
4. Fraimow HS, Jungkind DL, Lander DW, Delso DR, Deal JL. Urinary tract infection with an Enterococcus faecalis isolate that requires vancomycin for growth. Ann Intern Med 1994; 121: 22-26.
5. Rhinehart E, Smith NE, Wennersten C, Gors E, Greeman J, Eliopoulos GM. Rapid dissemination of beta-lactamase producing aminoglycoside-resistant Enterococcus faecalis among patients and staff on an infant-toddler surgical ward. N Engl J Med 1990; 323: 1.814-1.818.
6. Murray BE. The life and times of the enterococcus. Clin Microbiol Rev 1990; 3: 46-65.
7. Wells VD, Wong ES, Murray BE, Coudron PE, Williams DS, Markowitz DS. Infections due to betalactamase-producing high-level gentamicin-resistant Enterococcus faecalis. Ann Intern Med 1992; 116: 285-292.
8. Spera RV, Farber BF. Multiply-resistant Enterococcus faecium. The nosocomial pathogen of the 1990s. JAMA 1992; 268: 2.563-2.564.
9. Stevenson KB, Murray EN, Sarubbi FA. Enterococcal meningitis: report of four cases and review. Clin Infect Dis 1994; 18: 233-239.
10. Garrison RN, Fry DE, Berberich S, Polk HC Jr. Enterococcal bacteremia: clinical implications and determinants of death. Ann Surg 1982; 196: 43-47.
11. Barral DT, Kenney PR, Slotman GJ, Burchard KW. Enterococcal bacteriemia in surgical patients. Arch Surg 1985; 120: 57-63.
12. Maki DG, Agger WA. Enterococcal bacteremia: clinical features, the risk of endocarditis and management. Medicine 1988; 67: 248-269.
13. Celis G, Pallarés R, Ariza J, Cisnal M, Martín R, Gudiol F. Características clínicas y epidemiológicas de la bacteriemia por Enterococcus faecalis: estudio prospectivo de 80 episodios. Enferm Infecc Microbiol Clin 1988; 6: 454-459.
14. Gilmore MS. Enterococcus faecalis hemolysin/bacteriocin. En: Dunny GM, Cleary PP, McKay LL, eds. Genetics and molecular biology of streptococci, lactococci and enterococci. Washington, D.C.: American Society for Microbiology, 1991; 206-213.
15. Zervos MJ, Dembry L. Enterococcus in surgical infection: virulence, epidemiology, and resistance. Clin Infect Dis 1994; 3 Supl 1: 14-20.
16. Fontana R, Amalfitano G, Rossi L, Satta G. Mechanisms of resistance to growth inhibition and killing by betalactam antibiotics in enterococci. Clin Infect Dis 1992; 15: 486-489.
17. Kaye D. Enterococci. Biologic and epidemiologic characteristics and in vitro susceptibility. Arch Intern Med 1982; 142: 2.006-2.009.
18. Kim KS, Bayer AS. Significance of in-vitro penicillin tolerance in experimental enterococcal endocarditis. J Antimicrob Chemother 1987; 19: 475-485.
19. Schmidt JL. Efficacy of teicoplanin for enterococcal infections: 63 cases and review. Clin Infect Dis 1992; 15: 302-306.
20. Moellering RC Jr. Emergence of enterococcus as a significant pathogen. Clin Infect Dis 1992; 14: 1.173-1.178.
21. Fernández Guerrero ML, Barros C, Rodríguez JL, Soriano F. Aortic endocarditis due to Enterococcus faecalis highly-resistant to gentamicin. Eur J Clin Microbiol Infect Dis 1988; 7: 525-527.
22. Mortensen JE, LaRocco M. Enterococci: an old bug has learned new tricks. Clin Microbiol Newslet 1992; 14: 57-62.
23. Alonso T, Pérez JL, Liñares J. Enterococos: resistencia adquirida a los antibióticos. Enferm Infecc Microbiol Clin 1992; 10: 489-496.
24. Herman DJ, Gerding DN. Antimicrobial resistance among enterococci. Antimicrob Agents Chemother 1991; 35: 1-4.
25. Arthur M, Courvalin P. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother 1993; 37: 1.563-1.571.
26. Horodniceau T, Bougueleret L, El-Solh N, Bieth G, Delbos F. High-level, plasmid borne resistance to gentamicin in Streptococcus faecalis subspecies zymogenes. Antimicrob Agents Chemother 1979; 16: 686-689.
27. Wurtz R, Sahm D, Flaherty J. Gentamicin-resistant, streptomycin-susceptible Enterococcus faecalis bacteremia. J Infect Dis 1991; 163: 1.393-1.398.
28. Hindes RG, Willey SH, Eliopoulus GM et al. Treatment of experimental endocarditis caused by a beta-lactamase producing strain of Enterococcus faecalis with high-level resistance to gentamicin. Antimicrob Agents Chemother 1989; 33: 1.019-1.022.
29. Noble WC, Virani Z, Cree RGA. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiology Letter 1992; 93: 195-198.
30. Handwerger S, Perlman DC, Altarac D, Monka J, Marchione S, Shingh KV. Concomitant high-level vancomycin and penicillin resistance in clinical isolates of enterococci. Clin Infect Dis 1992; 14: 655-659.
31. Cercenado E, Eliopoulus G, Wennersten C, Moellering RC. Absence of synergistic activity between ampicillin and vancomycin against high-level vancomycin-resistant enterococci. Antimicrob Agents Chemother 1992; 36: 2.526-2.528.
32. Eliopoulus GM. Increasing problems in the therapy of enterococcal infections. Eur J Clin Microbiol Infect Dis 1993; 12: 409-412.
33. Piddock LJV. New quinolones and gram-positive bacteria. Antimicrob Agents Chemother 1994; 38: 163-169.
34. Fernández Guerrero ML, Rouse M, Henry N, Geraci E, Wilson NR. In vitro and in vivo activity of ciprofloxacin against enterococci isolated from patients with infective endocarditis. Antimicrob Agents Chemother 1987; 31: 430-434.
35. Eliopoulus GM, Wennersten CB, Cole G, Moellering RC. In vitro activities of two new glycylcyclines against gram-positive bacteria. Antimicrob Agents Chemother 1994; 38: 534-541.
36. Megran DW. Enterococcal endocarditis. Clin Infect Dis 1992; 15: 63-71.
37. Verdejo C. Endocarditis enterocócica. Revisión clínica y estudios en el modelo experimental de endocarditis por Enterococcus faecalis altamente resistente a gentamicina. Tesis Doctoral. Universidad Autónoma de Madrid, 1993.
38. Durack DT. Review of early experience in treatment of bacterial endocarditis, 1940-1955. En: Bisno AL, ed. Treatment of Infective Endocarditis. Nueva York: Grune & Stratton, 1981; 1-14.
39. Hunter TH. Use of streptomycin in treatment of bacterial endocarditis. Am J Med 1947; 2: 436-442.
40. Jawetz E, Gunnison JB, Coleman VR. The combined action of penicillin with streptomycin or chloromycetin on enterococci in vitro. Science 1950; 111: 254-257.
41. Geraci JE, Martin WL. Antibiotic therapy of bacterial endocarditis. VI. Subacute enterococcal endocarditis: clinical, pathologic and therapeutic considerations of 33 cases. Circulation 1954; 10: 173-182.
42. Koening MG, Kaye D. Enterococcal endocarditis: report of nineteen cases with long-term follow-up data. N Engl J Med 1961; 264: 257-264.
43. Robbins WC, Tompsett R. Treatment of enterococcal endocarditis and bacteramia: results of combined therapy with penicillin and streptomycin. Am J Med 1951; 10: 278-284.
44. Mandell GL, Kaye D, Levison ME, Hook EW. Enterococcal endocarditis: an analysis of 38 cases observed at the New York Hospital-Cornell Medical Center. Arch Intern Med 1970; 125: 258-264.
45. Wilson WR, Wilkowski C, Wright A, Sande MA, Geraci JE. Treatment of streptomycin-susceptible and streptomycin-resistant enterococcal endocarditis. Ann Intern Med 1984; 100: 816-823.
46. Almirante B, Tormnos MP, Gurgui M, Pujol M, Miró JM. Prognosis of enterococcal endocarditis. Rev Infect Dis 1991; 13: 1.248-1.254.
47. Rice LD, Calderwood SB, Eliopoulus GM, Farber BF, Karchmer AW. Enterococcal endocarditis: a comparison of prosthetic and native valve disease. Rev Infect Dis 1991; 13: 1-7.
48. Herzstein J, Ryan JL, Mangi RJ, Greco TP, Andriole VT. Optimal therapy for enterococcal endocarditis. Am J Med 1984; 76: 186-191.
49. Calderwood SA, Wennersten C, Moellering RC Jr, Kunz LJ, Krogstad DJ. Resistance to six aminoglycosidic aminocyclitol antibiotics among enterococci: prevalence, evolution and relationship to synergism with penicillin. Antimicrob Agents Chemother 1977; 12: 401-405.
50. Havard CWH, Garrod LP, Waterworth PM. Deaf or dead? A case of subacute bacterial endocarditis treated with penicillin and neomycin. Br Med J 1959; 1: 688.
51. Beaty HN, Turck M, Petersdorf RG. Ampicillin in the treatment of enterococcal endocarditis. Ann Intern Med 1966; 65: 701-707.
52. Greenwood D. Antibiotic resistance in enterococci. J Antimicrob Chemother 1989; 24: 631-635.
53. Moellering RC Jr. Treatment of enterococcal endocarditis. En: Sande MA, Kaye D, Root RK, eds. Endocarditis. Nueva York: Churchill Livingstone, 1984; 113-133.
54. Tight RR. Ampicillin therapy of experimental enterococcal endocarditis. Antimicrob Agents Chemother 1980; 18: 307-310.
55. Verdejo C, Arbol F, Fernández Roblas R, Castilla C, Fernández Guerrero ML. Therapy of experimental enterococcal endocarditis with amoxicillin. Resúmenes del VI European Congress of Clinical Microbiology and Infectious Diseases. Sevilla, 1993.
56. Wilkowske CJ. Enterococcal endocarditis. Mayo Clin Proc 1982; 57: 101-105.
57. Auckenthaler R, Wilson WR, Wright A, Washington JA, Durack DT, Geraci JE. Lack of in vivo bactericidal activity of N-formimidoyl thienamycin against enterococci. Antimicrob Agents Chemother 1982; 22: 448-452.
58. Fass RJ, Wright CA. Comparative efficacies of mezlocillin and ampicillin alone or in combination with gentamicin in the treatment of Streptococcus faecalis endocarditis in rabbits. Antimicrob Agents Chemother 1984; 25: 408-410.
59. 14C-labeled streptomycin by enterococci. J Clin Invest 1971; 50: 2.580-2.585.
60. Soriano F, Greenwood D. Action and interaction of penicillin and gentamicin on enterococci. J Clin Pathol 1979; 32: 1.174-1.177.
61. Carrizosa J, Levison ME. Minimal concentrations of aminoglycoside that can synergize with penicillin in enterococcal endocarditis. Antimicrob Agents Chemother 1981; 20: 405-411.
62. Wright AJ, Wilson WR, Matsumoto JY, Hnery NM, Geraci J. Influence of gentamicin dose size on the efficacies of combinations of gentamicin and penicillin in experimental streptomycin resistant enterococcal endocarditis. Antimicrob Agents Chemother 1982; 22: 972-975.
63. Holliman R, Smith E. Gentamicin-resistant enterococci and endocarditis. Postgr Med 1989; 65: 390-392.
64. Kathpalia S, Lolans V, Levandowski R. Resistance to all aminoglycoside antibiotics in enterococcal endocarditis. Clin Res 1984; 32: 372.
65. Libertin C, McKinley KM. Gentamicin-resistant enterococcal endocarditis: the need of routine screening for high-level resistance to aminoglycosides. South Med J 1990; 83: 458-490.
66. Lipman ML, Silva J. Endocarditis due to Enterococcus faecalis with high-level resistance to gentamicin. Rev Infect Dis 1989; 11: 325-327.
67. Spiegel CA, Huycke M. Endocarditis due to streptomycin-susceptible Enterococcus faecalis with high-level resistance to gentamicin. Arch Intern Med 1989; 149: 1.873-1.875.
68. Rice LB, Calderwood SB, Eliopoulos G, Farber BF, Karchmer AN. Enterococcal endocarditis: a comparison of prosthetic and native valve disease. Rev Infect Dis 1991; 13: 1-5.
69. Jones B, Ludlam HA, Brown DF. High-dose ampicillin for the treatment of high-level aminoglycoside resistant enterococcal endocarditis. J Antimicrob Chemother 1994; 33: 891-892.
70. Patterson JE, Colodny SM, Zervos MJ. Serious infection due to a beta-lactamase producing Streptococcus faecalis with high-level resistance to gentamicin. J Infect Dis 1988; 158: 1.144-1.145.
71. Thauvin C, Eliopoulus GM, Willey S, Wennertsten C, Moellering RC. Continuous-infusion ampicillin therapy of enterococcal endocarditis. Antimicrob Agents Chemother 1987; 31: 139-143.
72. Hellinger WC, Rouse MS, Rabadan PM, Henry N, Steckelberg JM, Wilson WR. Continuous versus intermittent ampicillin therapy of experimental endocarditis caused by aminoglycoside resistant enterococci. Antimicrob Agents Chemother 1992; 36: 1.272-1.275.
73. Burney S, Landman D, Quale J. Ramoplanin and penicillin therapy of experimental endocarditis due to multidrug-resistant Enterococcus faecium [resumen B71]. Interscience Conference on Antimicrobial Agents Chemotherapy. Orlando: American Society for Microbiology, 1994.
74. Brandt CM, Rouse M, Tallan NW, Lave NW, Stratton CM, Wilson WR et al. Effective treatment of multidrug-resistant enterococcal experimental endocarditis with combinations of cell-wall active agents [resumen b75]. Interscience Conference on Antimicrobial Agents Chemotherapy. Orlando: American Society for Microbiology, 1994.